We read with interest the paper of Pizzo et al. [1], confirming that adolescence is a key period for the diagnosis of 46,XY disorders of sex development (DSD) [2].
However, in our opinion, some points should be better addressed. Among these, we have the following.
The authors stated that the reported girl showed “normal intellectual function,” but this information had little relevance because mental function is not impaired in females with 46,XY DSD, reaching adolescence without any clinical suspicions. Indeed, this statement might be stigmatizing for these persons.
The statement that this adolescent was affected by hypergonadotropic hypogonadism (HH) is correct, according to the high LH and FSH values shown in Table 1 [1]. Very low levels of both 17β-estradiol and testosterone were also shown [1]. This endocrine pattern is not typical of late adolescent and young adult females with complete androgen insensitivity syndrome (CAIS) and intact testes. On the contrary, these persons show high/normal levels of both 17β-estradiol (for a person with a 46,XY karyotype) and testosterone [3–5]. In addition, adolescent/young adult women with CAIS did not show HH: LH is in high normal range or slightly elevated (due to the androgen resistance at central level), but FSH is in normal range (due to unaffected inhibin secretion from Sertoli cells) [3–5]. In addition, SHBG was reported within adult male range by Pizzo et al. [1], suggesting a normal sensitivity to the low levels of androgens in this girl [6]. Indeed, SHBG is within normal female range in women with CAIS, due to peripheral androgen resistance [5]. All these findings show poor agreement with the affirmed diagnosis of CAIS [1].
The clinical phenotype of the reported girl did not match with the phenotype of adolescents with CAIS; in fact, the latter shows normal breast development related to the relatively high normal estrogen levels and unopposed androgen action [3, 4, 7] and does not show hypotrophic breasts [1].
It is quite surprising that hormonal replacement therapy was started before any diagnosis was established.
Histological findings do not completely agree with the diagnosis of CAIS, in particular the absence of Leydig cells, which are abundant in adolescent females with CAIS and sometimes formed aggregates up to 2 mm in diameter [8, 9].
46,XY karyotype, female phenotype, and absence of mullerian derivatives may be present in several 46,XY DSD; they should be excluded before diagnosis of CAIS by optimal clinical, endocrine, and genetic investigations [10]. For example, the testosterone/Δ4-androstenedione ratio in the adolescent reported by Pizzo et al. [1] is very low (0.13; normal values >0.8 [11]). Thus, diagnoses of 17β-hydroxysteroid-dehydrogenase deficiency type 3 or 46,XY gonadal dysgenesis [11, 12] must be considered in the diagnostic process.
Risk of gonadal cancer largely varies among 46,XY DSD. For example, in CAIS is very low at least during the first two decades of life [13–15]. Thus, delayed gonadal removal can be recommended to permit both full sexual development [15] and better bone health [16]. If diagnosis of CAIS is certain, surgery can be postponed—at least until the legal age at which the propositus can participate in decision making [1, 15, 17–19].
We are concerned and in complete disagreement with the decision to perform gonadectomy without full disclosure and assent of the adolescent [17–19].
In conclusion, some findings are poorly consistent with a diagnosis of CAIS, which should be confirmed by molecular analysis of androgen receptor gene [2, 7]. In our experience, more than 25% of the females referred to our departments with clinical/endocrine diagnosis of CAIS did not have this diagnosis confirmed by genetic analysis [20].
Clinical approach should be changed according to the new guidelines for management of persons with 46,XY DSD and directly involving the girl in the decision process [2, 18, 21]. We also stress that multidisciplinary team evaluation in tertiary centers with documented experience in this field must be guaranteed to each person with 46,XY DSD for optimal holistic management [21], especially before performing irreversible surgical procedures.
Conflict of Interests
The authors declare that there is no conflict of interests regarding the publication of this paper.
Acknowledgment
We thank the Italian Network on Disorders of Sex Development (It-DSD) for scientific support. The constructive opinions of Italian and English Androgen Insensitivity Support Groups are also acknowledged.
PizzoA.LaganàA. S.BorrielliI.DugoN.Complete androgen insensitivity syndrome: a rare case of disorder of sex development20132013323269610.1155/2013/232696HughesI. A.HoukC.AhmedS. F.LeeP. A.Consensus statement on management of intersex disorders20069175545632-s2.0-3374577387010.1136/adc.2006.098319MeloK. F. S.MendoncaB. B.BillerbeckA. E. C.CostaE. M. F.InácioM.SilvaF. A. Q.LealA. M. O.LatronicoA. C.ArnholdI. J. P.Clinical, hormonal, behavioral, and genetic characteristics of androgen insensitivity syndrome in a Brazilian cohort: five novel mutations in the androgen receptor gene2003887324132502-s2.0-003762278610.1210/jc.2002-021658AudiL.Fernández-CancioM.CarrascosaA.AndaluzP.ToránN.PiróC.VilaróE.Vicens-CalvetE.GussinyéM.AlbisuM. A.YesteD.ClementeM.Hernández De La CalleI.Del CampoM.VendrellT.BlancoA.Martínez-MoraJ.GranadaM. L.SalinasI.FornJ.CalafJ.AngerriO.Martínez-SopenaM. J.Del ValleJ.GarcíaE.Gracia-BouthelierR.LapunzinaP.MayayoE.LabartaJ. I.LledóG.Sánchez Del PozoJ.ArroyoJ.Pérez-AytesA.BeneytoM.SeguraA.BorrásV.GabauE.CaimaríM.RodríguezA.Martínez-AedoM. J.CarreraM.CastañoL.AndradeM.Bermúdez De La VegaJ. A.Novel (60%) and recurrent (40%) androgen receptor gene mutations in a series of 59 patients with a 46,XY disorder of sex development2010954187618882-s2.0-7795164649310.1210/jc.2009-2146DoehnertU.BertelloniS.Richter-UnruhA.WernerR.HiortO.Hormone profiles in adolescents and adults with complete androgen insensitivity syndromeProceedings of the 3rd International Symposium on Disorders of Sex DevelopmentMay 2011Lübech, DenmarkSinneckerG.KöhlerS.Sex hormone-binding globulin response to the anabolic steroid stanozolol: evidence for its suitability as a biological androgen sensitivity test1989686119512002-s2.0-0024320594HughesI. A.DaviesJ. D.BunchT. I.PasterskiV.MastroyannopoulouK.MacDougallJ.Androgen insensitivity syndrome201238098511419142810.1016/S0140-6736(12)60071-3HannemaS. E.ScottI. S.Rajpert-de MeytsE.SkakkebækN. E.ColemanN.HughesI. A.Testicular development in the complete androgen insensitivity syndrome200620845185272-s2.0-3364467237110.1002/path.1890Kaprova-PleskacovaJ.StoopH.BrüggenwirthH.CoolsM.WolffenbuttelK. P.DropS. L.SnajderovaM.LeblJ.OosterhuisJ. W.LooijengaL. H.Complete androgen insensitivity syndrome: factors influencing gonadal histology including germ cell pathology20132013, article 19310.1038/modpathol.2013.193AhmedS. F.AchermannJ. C.ArltW.BalenA. H.ConwayG.EdwardsZ. L.ElfordS.HughesI. A.IzattL.KroneN.MilesH. L.O'TooleS.PerryL.SandersC.SimmondsM.WallaceA. M.WattA.WillisD.UK guidance on the initial evaluation of an infant or an adolescent with a suspected disorder of sex development201175112262-s2.0-7995880328810.1111/j.1365-2265.2011.04076.xBoehmerA. L. M.BrinkmannA. O.SandkuijlL. A.HalleyD. J. J.NiermeijerM. F.AnderssonS.De JongF. H.KayseriliH.De VroedeM. A.OttenB. J.RouwéC. W.MendonçaB. B.RodriguesC.BodeH. H.De RuiterP. E.Delemarre-Van De WaalH. A.DropS. L. S.17β-Hydroxysteroid dehydrogenase-3 deficiency: diagnosis, phenotypic variability, population genetics, and worldwide distribution of ancient and de novo mutations19998412471347212-s2.0-0033233294Faisal AhmedS.IqbalA.HughesI. A.The testosterone: androstenedione ratio in male undermasculinization20005366977022-s2.0-003449484210.1046/j.1365-2265.2000.01166.xPleskacovaJ.HersmusR.OosterhuisJ. W.SetyawatiB. A.FaradzS. M.CoolsM.WolffenbuttelK. P.LeblJ.DropS. L.LooijengaL. H.Tumor risk in disorders of sex development201044-52592692-s2.0-7995211141910.1159/000314536DeansR.CreightonS. M.LiaoL.-M.ConwayG. S.Timing of gonadectomy in adult women with complete androgen insensitivity syndrome (CAIS): patient preferences and clinical evidence20127668948982-s2.0-8486019216110.1111/j.1365-2265.2012.04330.xWünschL.HolterhusP. M.WesselL.HiortO.Patients with disorders of sex development (DSD) at risk of gonadal tumour development: management based on laparoscopic biopsy and molecular diagnosis2012110E958E9652-s2.0-8486030051010.1111/j.1464-410X.2012.11181.xBertelloniS.BaroncelliG. I.MoraS.Bone health in disorders of sex differentiation201044-52702842-s2.0-7795649771410.1159/000315961D'AlbertonF.Disclosing disorders of sex development and opening the doors201044-53043092-s2.0-7995210944610.1159/000317480WiesemannC.Ethical guidelines for the clinical management of intersex201044-53003032-s2.0-7995211413610.1159/000316232CullM. L.SimmondsM.Importance of support groups for intersex (disorders of sex development) patients, families and the medical profession201044-53103122-s2.0-7995211136610.1159/000313889BertelloniS.DatiE.BaldinottiF.ToschiB.MarroccoG.SessaM. R.MichelucciA.SimiP.BaroncelliG. I.NR5A1 gene mutations: clinical, endocrine and genetic features in two girls with 46, XY disorder of sex development201481210410810.1159/000354990BrainC. E.CreightonS. M.MushtaqI.CarmichaelP. A.BarnicoatA.HonourJ. W.LarcherV.AchermannJ. C.Holistic management of DSD20102423353542-s2.0-7795663104510.1016/j.beem.2010.01.006